Yu-Hwa Lo came to the Jacobs School in July of 1999. He has established a new lab to investigate biologically inspired photonic systems. A member of the Materials and Device Layer for the California Institute of Technology and Telecommuncations, he is collaborating with Professors Andy Kummel and William Trogler (Chemistry and Biochemistry) on early-warning biosensors. He is responsible for designing infrared photon counters in a joint effort with IBM's Almaden Research Center to build a quantum-communications system. He was Associate Professor of electrical engineering at Cornell University, prior to coming to UCSD. He received his Ph.D. from UC Berkeley in electrical engineering in 1987.
Dr. Rao works at the intersection of genomics and image informatics, across biological scale (cells, tissue and organ). He is interested in developing multi-modal decision algorithms that link and integrate various measurements (imaging, genomics etc) to characterize disease. His algorithms for phenotypic measurements encompass data from 2D/3D microscopy, radiology and histopathology. He is also interested in methodological aspects of genomic analysis and image assessment. In the context of these investigations, Dr. Rao collaborates with clinicians, biologists, engineers and data scientists.
Ejvind holds a PhD degree from University of Southern Denmark in Protein Chemistry & Molecular Biology. He has more than 20 years of experience in development of protein analyses and mass spectrometry methods in research & development of protein biologics; vaccines, monoclonal antibodies, therapeutic proteins as well as cell and gene therapies. He is experienced in project management and outsourcing collaboration projects with pharma/biotech, CMO/CROs as well as university research groups.
Dr. Mishra (Ex-Genentech, Ex-NCI, Ex-NIH) is the founding president and CEO of the American Association for Precision Medicine (AAPM) and chair of ACT –AAPM’s Coronavirus Taskforce. He is leading research efforts focused on preventing & curing chronic diseases; not only treating the sick but also providing knowledge/tools to individuals to live longer, healthier lives. He is also the founder and CEO of Agility Pharmaceuticals, a pharmaceutical company committed to revolutionizing drug discovery & development through technology, big data, robotics, and artificial intelligence. He is a serial entrepreneur who founded his first company after graduating high school, and his second company during his Ph.D. Since then, he has accumulated a wealth of experience by building, investing, and advising numerous other companies. He is an investor, co-founder/ board member of a few corporations, focused on accelerating drug discovery/ development, data analytics, robotics, mental health, and digital health. He is also the founder of AAPM Angels and Investors (AAi), an investment group focused on investing in drug discovery, diagnostics, precision medicine, technology & healthcare companies. He is also the founding investor and advisor to Barcelona Ventures and serves as an advisor to a $100M private equity fund.
Yu-Hwa Lo came to the Jacobs School in July of 1999. He has established a new lab to investigate biologically inspired photonic systems. A member of the Materials and Device Layer for the California Institute of Technology and Telecommuncations, he is collaborating with Professors Andy Kummel and William Trogler (Chemistry and Biochemistry) on early-warning biosensors. He is responsible for designing infrared photon counters in a joint effort with IBM's Almaden Research Center to build a quantum-communications system. He was Associate Professor of electrical engineering at Cornell University, prior to coming to UCSD. He received his Ph.D. from UC Berkeley in electrical engineering in 1987.
Matt Davis PhD joined Gritstone Oncology (NASDAQ: GRTS) in 2015 and is currently the Director of Molecular Biology and Sequencing responsible for various neo-antigen discovery and translational genomics efforts. Prior to Gritstone, Dr. Davis conducted post-doctoral research at Warp Drive Bio in the discovery biology group. He holds a PhD in Genetics from Yale with thesis research under the supervision of Dr. Joseph Schlessinger and previous to his graduate work he conducted cancer genomics research at Dana Farber Cancer Institute and the Broad Institute.
Jun Wang is an Associate Professor in the Department of Biomedical Engineering at Stony Brook University. Prior to joining SBU, he was an assistant professor in the Chemistry Department of SUNY Albany. He received postdoctoral training in the Department of Chemistry and the NanoSystems Biology Cancer Center at the California Institute of Technology. He obtained his Ph.D. in Biological Engineering from Purdue University. He has received several top awards including Chorafas Foundation prize.
Dr. Kelly is an Associate Professor in the Department of Chemistry and Biochemistry at Brigham Young University (BYU). He received his Ph.D. in analytical chemistry in 2005 from BYU and spent the next 13 years at Pacific Northwest National Laboratory where he began as a postdoc and ultimately served as Chief Technologist for the EMSL, a national scientific user facility. A central theme of Dr. Kelly’s research has been the development of new technological solutions for improved biochemical analyses, including mass spectrometry-based omics. Dr. Kelly has authored or coauthored nearly 100 publications and is a named inventor on 14 issued and pending patents, several of which have been licensed and commercialized. His work has been recognized with several awards including two R&D 100 awards, a Federal Laboratory Consortium Award for Excellence in Technology Transfer, the Georges Guiochon HPLC Faculty Fellowship and the HTC Innovation Award.
Ajay Nair’s research is focused on developing computational techniques to identify cellular regulatory interactions from high-throughput data. He completed his engineering master’s degree from IIT-Delhi holding first rank and Joint-PhD in Computational Biology from IIT-Bombay and Monash University, Australia. His postdoc training was with Prof. Andrea Califano and Prof. Robert Schwabe at Columbia University. Ajay and his team have identified regulatory interaction and identified drugs in Ovarian cancer and gastric cancer as well as identified and characterized disease causing fibroblasts in COVID-19 affected lungs, human ICC and liver metastases.